Smiths Medical plans to distribute its CADD infusion systems to non-hospital-based providers through a preferred partnership with Medical Specialties Distributors, the company reported today. As part of its new distribution model, Smiths will also make its infusion pumps and sets available to providers outside of the hospital setting through InfuSystem (NYSE:INFU) and Integrated Medical Systems. Get […]
Proteus Digital Health announced earlier this month that Anthem‘s (NYSE:ANTM) executive chairman, Joseph Swedish, joined the company’s board of directors. Swedish served as Anthem’s president & chief executive from 2013 until he was appointed executive chairman in 2018. Get the full story at our sister site, Drug Delivery Business News.
The U.S. District Court for the Central District of California has dismissed a class action lawsuit against InfuSystem (NYSE:INFU) alleging that the company, its ex-CEO and former chief finance executive violated federal securities laws by misleading investors with its financial statements. The case was brought against InfuSystem in Nov. 2016, after the company and its former CEO, […]
Former AcuFocus CEO Mazzo moves to head Ophthamology at Zeiss Carl Zeiss Meditec (ETR:AFX) said this week it tapped ex-AcuFocus CEO James Mazzo as the global president of its ophthalmology business as well as managing the entire company’s U.S. sales and service center. Mazzo comes from a 3-year run as president and CEO at AcuFocus, where […]
InfuSystem Holdings (NSDQ:INFU) said today it bought the infusion pumps assets of Philadelphia-based ambulatory infusion pump provider InfusAid for an undisclosed amount. Madison Heights, Mich.-based InfuSystem said it will acquire approximately 400 infusion pumps from InfusAID as part of the purchase agreement. “Similar to our acquisition of Ciscura in 2015, the pumps we acquire from […]
Edwards Lifesciences (NYSE:EW) said it will re-state its financial results for the first 3 quarters of 2011, “due to certain technical errors in the balance sheets and cash flow statements for these interim periods.”
The Irvine, Calif.-based heart valve maker said the errors involve the mis-statement of short-term investments as cash & equivalents, plus the way it treated tax benefits from stock plans.